UK markets open in 3 hours 50 minutes

Silence Therapeutics plc (SLN)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
21.80+0.05 (+0.23%)
At close: 3:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close21.75
Open21.80
Bid21.22 x 1000
Ask21.81 x 800
Day's range21.80 - 21.80
52-week range15.00 - 35.00
Volume1,141
Avg. volume1,500
Market cap652.38M
Beta (5Y monthly)1.22
PE ratio (TTM)N/A
EPS (TTM)-2.01
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2,314.82
  • Globe Newswire

    Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

    Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day Announces plans to initiate a Phase 1 study in polycythaemia vera (PV) with SLN124, the third indication being assessed using endogenous hepcidin modulation SLN360 single-ascending dose study on-track for topline data in Q1’22 – independent review committee recommends extending follow-up period to assess potential longer duration of actionAdvancing mRNAi GOLD™ platform programs – poised to deliver 2-3 INDs pe

  • Globe Newswire

    Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market

    Silence Announces Proposed Cancellation of Admission of its Ordinary Shares to Trading on AIM and Transition of its Primary Trading Venue to the Nasdaq Global Market Notice of General Meeting to be held on 1 November 2021 15 October 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medic

  • Globe Newswire

    Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform

    Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence’s mRNAi GOLD™ Platform Hansoh will make a $16 million upfront cash payment and Silence has the potential to receive up to $1.3 billion in milestones Silence gains exclusive rights to two targets in all territories except the China region; Hansoh has rights to those two targets in the China region and global rights to a third target 15 October 2021 LONDON and SHANGHAI, Silence Therapeutics plc